1,1-(1,2-Ethanediylbis(oxy))bis(2,4,6-tribromobenzene), 97%, 25g

6-BROMO-4-CHLORO-7-METHOXYQUINOLINE, 95.0%, 100mg

3-(5-Aminoisoxazol-3-yl)phenol, 97%, 1g

2-Chloro-5-fluoro-6-methoxynicotinic acid, 95.0%, 1g

Pyrrolidin-3-ylmethanol hydrochloride hydrate, 95.0%, 1g

1-(1-Methyl-1H-indazol-4-yl)ethanone, 95.0%, 500mg

2-(3-Bromophenyl)-1,3-thiazole-4-carboxylic acid, 97.0%, 5g

1-(3,5-Dichlorophenyl)-2,2,2-trifluoroethanol, 98%, 250mg

Long working distance plan phase Fluarex contrast 20x/0.45 infinity corrected IOS objective, corrected for 1 mm petri dish thickness

Methyl 3-sulfamoylbenzoate, 95.0%, 1g

3-bromo-2-methyl-6-(4H-1,2,4-triazol-4-yl)pyridine, 95.0%, 1g

3-(Piperidin-1-ylsulfonyl)benzoic acid, 95.0%, 5g

Methyl 5-Bromopyrimidine-2-carboxylate, 98.0%, 10g